AlivaMab Biologics

Name

AlivaMab Biologics

Legal name

AlivaMab Biologics, LLC

Website

https://alivamab.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Antibody Drug Discovery Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Antibody drug discovery
• Therapeutic antibody services
• Transgenic mouse platform
• Biologics engineering services
• Human antibody generation

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Fee-for-Service Antibody Discovery: Contract research services providing end-to-end antibody drug discovery and engineering. Partners engage AMB for discovery and engineering services using the AlivaMab Mouse platform on a fee-for-service basis. Now available milestone- and royalty-free for service partners.
2. Platform Licensing: Non-exclusive licensing of AlivaMab Mouse technology to pharmaceutical and biotechnology companies for their own internal antibody discovery programs. Multiple companies have licensed the technology including global pharmaceutical companies.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

AlivaMab Biologics provides end-to-end contract research services for the discovery and engineering of fully human therapeutic antibodies, anchored by its patented AlivaMab Mouse transgenic platform and complemented by proprietary immunization, screening, and engineering methodologies. The company offers partners customizable capability modules (discovery, engineering, bispecifics, CARs, developability) on a fee-for-service basis, now available milestone- and royalty-free, with additional non-exclusive licensing of the AlivaMab Mouse technology to pharmaceutical and biotechnology companies for internal programs.

Product overview

AlivaMab Biologics provides a fully integrated platform for biologics drug discovery and engineering through modular, customizable capability modules. The core technology is the AlivaMab Mouse transgenic platform, which includes multiple strains (AlivaMab Mouse-NGX, AlivaMab Mouse-SDX) for generating human therapeutic antibodies. These are complemented by proprietary methodologies including AMMPD Immunizations, Fit-for-Purpose Screening, Immune Repertoire Display, and Bispecific Formats. The platform includes supporting capabilities such as Alivalign software for in silico analysis, CAR Engineering, Developability Assessment, and NGS-Based Hit Expansion. The company offers these as discrete capability modules that partners can select individually or engage across the full spectrum for end-to-end biologics discovery programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Antibody Discovery Services
• Antibody Engineering Services
• AlivaMab Mouse Platform Licensing
• AlivaMab Mouse-NGX
• Milestone- and Royalty-Free Discovery Service
• T-Cell Engager and Multispecific Engineering Services
• Developability Assessment Service

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Seven partnerships are on record, tiered core, major and strategic.

• Ablexis, LLCcoreStrategic or Co-development PartnerSister company that creates and licenses the AlivaMab Mouse technology. Both companies share leadership under Larry Green (CEO of both). AlivaMab Biologics provides integrated discovery services using Ablexis technology. Together they form the primary antibody discovery platform offering.
• Janssen Research & Development, LLCmajorStrategic or Co-development PartnerMulti-target discovery agreement where ADS provides expertise and capabilities to generate and deliver therapeutic antibody candidates to Janssen for further evaluation. Part of Johnson & Johnson.
• Teva PharmaceuticalsmajorStrategic or Co-development PartnerMulti-target agreement for generating diverse panels of fully human antibodies for multiple therapeutic programs. Leverages ADS discovery platform including AMMPD immunization technologies.
• Tanabe Research Laboratories USAmajorStrategic or Co-development PartnerDiscovery partnership with subsidiary of Mitsubishi Tanabe Pharma Corporation. ADS provides expertise and capabilities using AlivaMab Mouse platform for integrated antibody drug discovery collaboration.
• Almirall, S.A.majorStrategic or Co-development PartnerMulti-target licensing agreement between Ablexis and Almirall for use of AlivaMab Mouse technology for discovery, development and commercialization of antibodies. ADS conducts the drug discovery research for Almirall focusing on dermatological conditions.
• Berkeley Lights, Inc.strategicTechnology or IntegrationCollaboration to identify diverse panel of anti-SARS-CoV-2 human antibodies. Combined Ablexis AlivaMab Mouse, ADS immunization expertise, and Berkeley Lights Beacon platform for single cell selection and functional screening.
• IGM BiosciencesmajorStrategic or Co-development PartnerRapidly expanding list of partners utilizing ADS discovery and engineering capabilities for antibody drug development.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Broad incumbents

• Lonza Biologics: Lonza provides integrated biologics development and manufacturing services, including antibody-related discovery and cell line development. It is a broad incumbent offering overlapping capabilities as part of a much larger service portfolio.
• WuXi Biologics: WuXi Biologics is a large global CRO/CDMO offering end-to-end biologics discovery, development, and manufacturing services including antibody discovery. It competes broadly on integrated service offerings and has substantially greater scale than AlivaMab Biologics.
• GenScript ProBio: GenScript ProBio offers antibody discovery, development, and manufacturing services as part of a broader life sciences services portfolio. It is a broad incumbent serving pharma and biotech customers with bundled biologics offerings.

Direct peers

• Adimab: Adimab provides yeast display-based antibody discovery and engineering services to pharma and biotech. It is a direct competitor offering an alternative display-based platform for fully human therapeutic antibody generation with similar fee-for-service and partnership models.
• AbCellera Biologics: AbCellera is a leading antibody discovery platform combining single-cell screening, AI, and a proprietary technology stack for fully human antibody discovery. It serves the same pharma/biotech customer base and is a direct competitor in antibody discovery CRO services.
• Trianni (Alloy Therapeutics): Trianni, now part of Alloy Therapeutics, licenses transgenic mouse platforms (Trianni Mouse) for fully human antibody discovery. It is a direct competitor offering alternative transgenic technology to pharma for internal and partnered antibody programs.
• OmniAb: OmniAb operates a discovery platform combining proprietary transgenic animals (OmniRat, OmniMouse, OmniChicken) and AI for therapeutic antibody discovery. It is a direct competitor in the transgenic-platform antibody discovery space and has overlapping pharma customers.
• Kymab (Sanofi): Kymab operated the IntelliSelect transgenic mouse antibody discovery platform before being acquired by Sanofi in 2021. It was a direct peer offering competing transgenic antibody technology to pharma partners prior to acquisition.

Emerging players

• Harbour BioMed: Harbour BioMed operates the H2L2 transgenic mouse platform for fully human antibody discovery and develops its own pipeline. It is an emerging player with overlapping platform technology and a partial overlap in target customer base.

Others

• Ablexis: Ablexis is the sister company that owns and licenses the AlivaMab Mouse transgenic platform under shared CEO Larry Green. It is a closely related entity rather than a competitor, but is directly comparable as a platform licensor in the antibody discovery space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/alivamab-biologics

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AlivaMab Biologics